Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. Results suggest that venetoclax is only active in a small cohort of patients therefore we wanted to determine its efficacy when used in combination. Combining...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Leukemia
Main Authors: Matulis, Shannon M., Gupta, Vikas A., Nooka, Ajay K., Von Hollen, Hayley, Kaufman, Jonathan L., Lonial, Sagar, Boise, Lawrence H.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874660/
https://ncbi.nlm.nih.gov/pubmed/26707935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.350
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares